Amgen’s $1.9B Five Prime deal adds to cancer drug pipeline and Asia strategy

Published on:

The acquisition brings Amgen a novel Phase 3-ready drug for gastric cancers. For Five Prime Therapeutics, the deal is a lifeline following a series of clinical and financial setbacks that left much of the biotech’s fortunes resting on its lead antibody drug.

Read more    Source: medcitynews.com

Leave a Reply